Monosomy 7 Treatment Approach

Immediate Risk Stratification and Treatment

The American College of Hematology recommends allogeneic hematopoietic stem cell transplantation (HSCT) as the definitive treatment for monosomy 7, due to its association with poor response to chemotherapy alone, high relapse rates, and dismal outcomes without transplantation, with a high-risk cytogenetic abnormality across all myeloid malignancies 1
Monosomy 7 requires immediate evaluation for HSCT candidacy, with a prognosis that varies by disease context 1

The European Society for Medical Oncology recommends performing high-resolution molecular HLA typing (classes I and II) immediately at diagnosis for all patients aged <55 years who are HSCT candidates, and initiating unrelated donor search simultaneously if no matched sibling is available 1
Serial somatic gene panels from bone marrow must be performed at baseline and with each subsequent evaluation, particularly screening for high-risk mutations including SETBP1, ASXL1, RUNX1, and RAS pathway genes, with approximately 50% of patients with monosomy 7 acquiring additional leukemia-driver mutations indicating progression risk 1
Cytogenetic analysis should be performed to identify additional chromosomal abnormalities, with ≥20 metaphases analyzed 2

For AML with monosomy 7, the National Comprehensive Cancer Network recommends induction chemotherapy as a bridge to transplant, with standard "7+3" induction: cytarabine 100-200 mg/m² continuous infusion for 7 days plus daunorubicin 60-90 mg/m² or idarubicin 12 mg/m² on days 1-3, and proceeding to myeloablative allogeneic HSCT in first complete remission without delay for consolidation chemotherapy cycles 2
Intensive chemotherapy alone shows poor outcomes with frequent treatment resistance and early relapse, emphasizing the need for HSCT 1

Patients with germline predisposition syndromes, such as GATA2 deficiency, Fanconi Anemia, or SAMD9/SAMD9L mutations, should proceed directly to allogeneic HSCT when monosomy 7 is detected, due to their particularly high risk of malignant transformation 1
The American Society of Hematology recommends monitoring for clonal evolution in Ph-negative cells, as monosomy 7 or del(7q) in Ph-negative cells indicates risk of myelodysplasia and acute leukemia, justifying long-term follow-up bone marrow biopsies 3